Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Sunder-Plassmann

Showing results (11-20 of 100) with videos related to

Pageof 10
Sort By:
Hemodialysis International. International Symposium on Home Hemodialysis|April 29, 2017
Pathophysiology and Treatment of Hyperhomocysteinemia in End-Stage Renal Disease PatientsG Sunder-Plassmann, Walter H Hörl
Clinical Nephrology|March 1, 1997
Erythropoietin and ironG Sunder-Plassmann, W H Hörl
Mineral and Electrolyte Metabolism|February 22, 2000
Molecular genetics of homocysteine metabolismM Födinger, H Buchmayer, G Sunder-Plassmann
Current Opinion in Urology|April 29, 2000
Hyperhomocysteinemia in organ transplantationG Sunder-Plassmann, A Floth, M Födinger
Clinical Nephrology|December 5, 2006
Metabolic alkalosis in a hemodialysis patient--successful treatment with a proton pump inhibitorB M Kirsch, G Sunder-Plassmann, C Schwarz
Journal of Nephrology|March 17, 2000
Molecular biology of 5,10-methylenetetrahydrofolate reductaseM Födinger, W H Hörl, G Sunder-Plassmann
Journal of Internal Medicine|May 19, 2004
The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapyA C Hauser, M Lorenz, G Sunder-Plassmann
European Journal of Clinical Investigation|November 12, 2005
Intravenous iron therapy: well-tolerated, yet not harmlessG Sengölge, W H Hörl, G Sunder-Plassmann
Wiener Klinische Wochenschrift|June 23, 1999
[Trends in molecular diagnosis]M Födinger, G Sunder-Plassmann, O F Wagner
Expert Opinion on Investigational Drugs|November 4, 2000
Therapeutic potential of total homocysteine-lowering drugs on cardiovascular diseaseG Sunder-Plassmann, W C Winkelmayer, M Födinger
Pageof 10

Showing results (11-20 of 100) with videos related to

Sort By:
Pageof 10
Hemodialysis International. International Symposium on Home Hemodialysis|April 29, 2017
Pathophysiology and Treatment of Hyperhomocysteinemia in End-Stage Renal Disease PatientsG Sunder-Plassmann, Walter H Hörl
Clinical Nephrology|March 1, 1997
Erythropoietin and ironG Sunder-Plassmann, W H Hörl
Mineral and Electrolyte Metabolism|February 22, 2000
Molecular genetics of homocysteine metabolismM Födinger, H Buchmayer, G Sunder-Plassmann
Current Opinion in Urology|April 29, 2000
Hyperhomocysteinemia in organ transplantationG Sunder-Plassmann, A Floth, M Födinger
Clinical Nephrology|December 5, 2006
Metabolic alkalosis in a hemodialysis patient--successful treatment with a proton pump inhibitorB M Kirsch, G Sunder-Plassmann, C Schwarz
Journal of Nephrology|March 17, 2000
Molecular biology of 5,10-methylenetetrahydrofolate reductaseM Födinger, W H Hörl, G Sunder-Plassmann
Journal of Internal Medicine|May 19, 2004
The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapyA C Hauser, M Lorenz, G Sunder-Plassmann
European Journal of Clinical Investigation|November 12, 2005
Intravenous iron therapy: well-tolerated, yet not harmlessG Sengölge, W H Hörl, G Sunder-Plassmann
Wiener Klinische Wochenschrift|June 23, 1999
[Trends in molecular diagnosis]M Födinger, G Sunder-Plassmann, O F Wagner
Expert Opinion on Investigational Drugs|November 4, 2000
Therapeutic potential of total homocysteine-lowering drugs on cardiovascular diseaseG Sunder-Plassmann, W C Winkelmayer, M Födinger
Pageof 10